Drugs / BAT4406F
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04146285 | Sep 2020 → Mar 2023 | neuromyelitis optica | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06044350 | Aug 2023 → May 2026 overdue | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Bio-Thera Solutions | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07499700 | Oct 2025 → Oct 2030 expected | focal segmental glomerulosclerosis, minimal change disease | Bio-Thera Solutions | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT4406F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06044350 ↗ |
| Action | Deplete | “BAT4406F led to a rapid and significant B-cell depletion in all dose groups.” PMID 39592888 ↗ Nov 2024 |
| Modality | Monoclonal antibody | “an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced fully humanized anti-CD20 monoclonal antibody” PMID 39592888 ↗ Nov 2024 |
| Route | Intravenous | “subjects will receive BAT4406F injection via intravenous infusion.” NCT04146285 ↗ |